Home > Journals > International Angiology > Past Issues > International Angiology 2011 August;30(4) > International Angiology 2011 August;30(4):299-320

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

INTERNATIONAL ANGIOLOGY

A Journal on Angiology


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899


eTOC

 

REVIEWS  


International Angiology 2011 August;30(4):299-320

language: English

Anticoagulant drugs: what is new?

Kei A. 1, Florentin M. 1,2, Elisaf M. S. 1, Liberopoulos E. N. 1

1 Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece
2 Department of Clinical Biochemistry (Vascular Prevention Clinics), Royal Free campus,
University College London Medical School, University College London (UCL), London UK


PDF  


Heparins and vitamin K antagonists have been the cornerstones of anticoagulation treatment for several decades. Despite their effectiveness, these agents have limitations which can include food and drug interactions and the need for monitoring. It follows that there is a need for new anticoagulants. There are numerous promising agents at various stages of evaluation. Those in the most advanced stages of development are the oral factor Xa and the thrombin inhibitors, which are the focus of this review.

top of page

Publication History

Cite this article as

Corresponding author e-mail

vaglimp@yahoo.com